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Background: Neurologic impairments in female heterozygotes for X-linked Adrenoleukodystrophy (X-ALD) are
poorly understood. Our aims were to describe the neurological and neurophysiological manifestations of a cohort
of X-ALD heterozygotes, and to correlate them with age, disease duration, mutations, X-inactivation and serum
concentrations of a marker of neuronal damage, neuron-specific enolase (NSE).
Methods: All 45 heterozygotes identified in our region, with previous VLCFA and molecular diagnosis, were
invited to be evaluated through myelopathy scales JOA and SSPROM, nerve conduction studies and
somatosensory evoked responses. X inactivation pattern was tested by HUMARA methylation assay. Serum NSE
was measured by eletrochemiluminescense.
Results: Thirty three heterozygote women were recruited: 29 (87%) were symptomatic. Symptomatic and
asymptomatic women presented different m ± sd ages (43.9 ± 10.2 versus 24.3 ± 4.6), JOA (14.5 ± 1.7 versus 16.6 ± 0.2)
and SSPROM (86.6 ± 7.9 versus 98.4 ± 1.1) scores (p < 0.05). Both JOA (r = −0.68) and SSPROM (r = −0.65) correlated with
age, irrespectively of the disease status (p = 0.0001, Spearman). Delayed latencies in the central ascending conduction
studies on the lower limbs were present in 72% of all heterozygotes, and correlated with SSPROM (r = −0.47, p = 0.018,
Spearman). NSE values were higher in heterozygote than in control women (12.9 ± 7 and 7.2 ± 7 ng/ml, p = 0.012,
Mann-Whitney U). Mutation severity and inactivation patterns were not associated with neurologic status.
Conclusion: Neurologic manifestations, clearly related to age, were quite common in the present cohort. JOA and
SSPROM scales were able to discriminate the asymptomatic from the symptomatic heterozygotes. Both scales might
be useful tools to follow disease progression, in future studies.
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X-linked adrenoleukodystrophy (X-ALD, OMIM #300100)
is the most common peroxisomal disorder worldwide
[1,2]. Affecting the metabolism of saturated very long
chain fatty acids (VLCFAs), X-ALD is caused by a defect
in ABCD1 gene that codes for ALD protein [3], a peroxi-
somal membrane protein that belongs to the ATP-binding
cassette superfamily of membrane transport proteins [4].
ABCD1 mutations give rise to obvious phenotypes in
hemizygote men, such as the classical cerebral form of
ALD (CALD) and the adrenomyeloneuropathy (AMN),
among others [4].
A very limited number of studies addressed manifesta-
tions in female carriers; some authors stated that af-
fected women are under recognized and undertreated
[5]. Early reports said that 20 to 50% of heterozygotes
might present a mild to severe myeloneuropathy that re-
sembles AMN, this clinical picture being related to ageing
[6]. The myelopathic component of AMN is characterized
by a distal axonopathy that affects the dorsal column
and the corticospinal tract [7]. Neurophysiologic stud-
ies showed central and peripheral abnormalities and
suggested the prominence of axonal dysfunction [8].
VLCFA were established a long time ago as bio-
markers for X-ALD. Elevated plasma VLCFA levels are
the diagnostic gold-standard for X-ALD in men and
present 15-20% of false negative results in women, for
whom a molecular investigation is the main diagnostic
tool [4].
In addition to diagnostic concerns, there are no rea-
sonable mechanistic explanations for the variability
regarding the presence and absence of neurological
impairments in heterozygote females. Although brain
VLCFA levels correlated with CALD in hemizygotes
[9], plasma VLCFA levels have never been related to
X-ALD phenotypes in men and women [4]. It is well
known that genotypes do not correlate with phenotypes,
in X-ALD [4]. Skewed X chromosome inactivation was
also investigated, bringing contradictory results [10-12].
Alterations in oxidative stress parameters such as thiobar-
bituric acid-reactive substances [13] have been described
in female carriers, without further exploring their poten-
tial associations with phenotypes.
Therefore, clinical and biochemical biomarkers of dis-
ease progression in heterozygotes for X-ALD are lacking.
In this sense, we aimed to describe the symptomatic status
of our X-ALD heterozygote cohort; to measure the neuro-
logical manifestations through myelopathy scales JOA and
SSPROM, peripheral nerve conduction studies and som-
atosensory evoked responses; to measure plasma levels of
a neuron disease marker, neuron-specific enolase (NSE);
and to look for associations between these parameters and
independent variables such as age, age at onset, mutations,
X inactivation pattern and plasmaVLCFA.Methods
Population and clinical evaluations
All women previously identified as heterozygotes for
X-ALD, in South Brazil, were invited to participate in
this study. All had molecular analyses and VLCFA dos-
ages performed in our institution, as reported else-
where [14]. To be included, they had to be over 18
years old and give the informed consent. Exclusion criteria
were the presence of any abnormality on the following
exams at recruitment: lymphocytes count, hemoglobin,
erythrocytes median corpuscular volume, sedimentation
rate, vitamin B12, thyroid stimulating hormone, proteino-
gram, VDRL (Venereal disease research laboratory),
FTA-Abs (Fluorescent Treponemal Antibody- absorption),
antibodies anti-HTLV (Human T lymphotropic virus) and
Anti-HIV (Human Immunodeficiency Virus), oxalacetic
and glutamic pyruvic transaminases, qualitative urine test,
thrombocytes, glucose and creatine.
The interview started with an open question about any
disability or presence of symptoms in the heterozygote.
After that, the interviewer (CTH) described the symp-
toms of spasticity, paraparesis, sensory losses and loss of
sphincter control, and explained that these symptoms
could be present in heterozygote females. After that, the
interviewer asked again about the presence and age at
onset (AO) of motor disability, sensory losses and/or
loss of sphincter control and the answer to this was
taken into account. Heterozygote women were then clas-
sified according to their responses; as symptomatic if
complaints of neuropathic pain, paresthesia, sphincter
dysfunction or paresis were present, or as asymptomatic
if these complaints were absent. Data such as age, AO,
disease duration (DD), family and ABCD1 mutations
were collected.
Neurological impairment and disability were evaluated
through two myelopathy scales: the Japanese Ortho-
paedic Association (JOA) [15] and the Severity Score
System for Progressive Myelopathy (SSPROM) [16]. JOA
includes questions about motor disability of upper and
lower limbs, about sensory losses and about sphincter
function. SSPROM includes questions about these
same domains, plus questions about motor strength
and tonus/reflexes. In this sense, both scales measure
disability as well as neurological impairment.
We elected two SSPROM domains to measure dis-
ability. SSPROM’s motor disability domain was based
on and mirrors the Overall Disability Sum Score [17],
while SSPROM’s sphincter domain was based and re-
capitulates the “sphincter dysfunction” domain of
Kurtzke functional systems scores [18]. An overall
disability evaluation was then measured by these two
SSPROM domains (0 to 50 points; Table 1). Since a
minimally important difference has not been deter-
mined for the disability parameters so far, we have
Table 1 Clinical characteristics of the local cohort of X-ALD heterozygote women
X-ALD heterozygotes p*
All heterozygotes participant Symtomatic Asymtomatic
N (families) (16) 33 29 4
Age at examination 41.2 ± 11.9 43.9 ± 10.2 24.3 ± 4.6 0.005
(24–61) (20–30)
Age at onset of symptoms 39.4 ± 10 (21–59)
Disease duration 4.5 ± 3.3
JOA (range: -2 to17) 14.8 ± 1.8 14.5 ± 1.7 16.6 ± 0.2 0.005
SSPROM (range: 0 to 100) 88 ± 8.4 86.6 ± 7.9 98.4 ± 1.1 0.001
SSPROM Motor Disability (range: 0 to 30) 27.6 ± 2.6 27.3 ± 2.6 30 ± 0 0.023
SSPROM Motor Strength (0 to 20) 18.9 ± 2 19.1 ± 1.3 17.5 ± 5 ns
SSPROM sensory losses (0 to 20) 16.4 ± 2.4 16.1 ± 2.3 18.5 ± 9 ns
SSPROM spasticity/ hyperreflexia (0 to 10) 6.1 ± 2.1 5.7 ± 1.8 9.4 ± 1.2 0.05
SSPROM sphincter contro (0 to 30) 27.6 ± 2.6 17.8 ± 2.3 20 ± 0 ns
*Mann-Whitney U.
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were already disabled.
In order to produce a “disease severity score” where
the neurological impairment was corrected by the dis-
ease duration, the SSPROM reciprocate of each woman
was divided by disease duration. This severity score was
then compared among groups stratified by risk factors
such as mutation position, mutation severity, NSE and
inactivation patterns.
Blood samples were taken and neurophysiological stud-
ies (described below) were performed within 15 days of
evaluation.
Neurophysiological studies
Motor and sensory nerve conduction studies in several
nerves were performed in the right side of the body
(Table 2). Motor conduction velocity (m-NCV), distal la-
tency and amplitude for both compound muscle action
potential (CMAP) and sensory nerve action potential
(SNAP) were measured according to standard tech-
niques in which normal values were considered within
2-SD from the mean [19].
Somatosensory evoked responses (SSER) were mea-
sured using the 10/20 electrode placement international
system and recorded according to standard techniques
[19]. The latencies of N8, P40 and N50 were recorded
after tibial nerve stimulation, and N9 and N20 after me-
dian nerve stimulation. Only P40 and N20 latencies were
included into regression analyses. Normal latency values
were considered according to Chiappa [20] and based on
the patient’s height. The upper limits of normal values
were given in Table 3.
Both, nerve conduction studies and SSER were per-
formed using a Nihon –Kohden (Neuropack S1 MEB-
9400 K) 4 channel EMG/EP system.VLCFA
Plasma docosanoic (C22:0), tetracosanoic (C24:0) and
hexacosanoic (C26:0) acids were obtained previously to
the present study, and were analyzed as described by
others [21]. Values of C26:0 (in µm/L) and of discrim-
inant factor 3,805(C24:0/C22:0) + 5,296(C26:0/C22:0) +
5,15(C26:0) [22] were studied in the present heterozygote
females. The discriminant factor’s value of 10.86 discrimi-
nated X-ALD heterozygote from normal homozygote
women, with 15% of false-negative results.
Enolase quantification
Serum NSE was measured using an eletrochemilumines-
cent assay provided by Roche DiagnosticsR, Indianapolis,
IN, a double sandwich assay that uses an antibody anti-
NSE bound with ruthenium (luminescent label). The
reaction and quantification were performed by Elecsys-
2010 (Roche). No hemolyzed samples were used. The
assay was carried out in duplicate and the confidence
variance was within 5%. NSE concentrations were also
measured in thirteen unrelated, normal women used as
a control group.
Inactivation studies
Genomic DNA was obtained from peripheral leukocytes
by the salting out procedure [23]. X-inactivation patterns
were assessed for skewing with the human androgen-
receptor locus (HUMARA) methylation assay [24]. Prior
to digestion, informative women were identified by PCR
at HUMARA locus and capillary electrophoresis. For the
informative women (n = 20), digestion of 100 ng gen-
omic DNA with the methylation-sensitive restriction
endonuclease, HpaII, and subsequent PCR amplification
of the HUMARA polymorphic CAG repeat was used to
determine X-inactivation status in X-ALD heterozygotes.
Table 2 Nerve conduction studies according to the presence or absence of symptoms of 22 ×-ALD heterozygote
women
Neuroconduction studies, right side (Mean ± sd) (range) All 22
heterozygotes
Presence of symptoms p*
Symptomatic (20) Asymptomatic (2)
Motor conduction velocity (m/s) Median 57 ± 6.2 (47–73) 56.9 ± 6.5 58.9 ± 2.2 ns
(results above the cutoff value of 49,2) (2) (0)
Fibular 48.1 ± 5 (40–55) 47.3 ± 4.9 53.2 ± 1 ns
(results above the cutoff value of 45.3) (3) (0)
Tibial 49.5 ± 4.6 (44–63) 49.2 ± 4.6 54.4 ns
(results above the cutoff value of 39.9) (0) (0)
Sensitive conduction velocity (m/s) Median 49.4 ± 3.9 (42–59) 49.2 ± 4 52 ± 2 ns
(results above the cutoff value of 51.7) (12) (0)
Ulnar 52.6 ± 6 (44–66) 52.8 ± 6.3 51.3 ± 0.6 ns
(results above the cutoff value of 53.8) (3) (0)
Fibular superficial 53.7 ± 5.7 (44–64) 53.1 ± 5.4 58.4 ± 7.5 ns
(results above the cutoff value of 35) (0) (0)
Motor conduction amplitude (mV) Median 9 ± 3.6 (2–16) 9 ± 3.7 9.2 ± 0.5 ns
(results under the cutoff value of 3.3) (1) (0)
Fibular 4 ± 1.9 (1–7) 4 ± 1.8 3.9 ± 3.2 ns
(results under the cutoff value of 1.6) (1) (0)
Tibial 7.7 ± 4.7 (2 to 19) 7.6 ± 5 8.1 ± 2.3 ns
(results under the cutoff value of 2,8) (1) (0)
Sensitive conduction amplitude (μV) Median 14.5 ± 5.8 (5 to 29) 14.5 ± 5.9 15.2 ± 7 ns
(results under the cutoff value of 15.1) (3) (0)
Ulnar 11.3 ± 6 (5 to 27) 11.4 ± 6.4 10.9 ± 3.3 ns
(results under the cutoff value of 5.8) (0) (1)
Fibular 15.3 ± 6.6 (5 a 30) 15.3 ± 6.5 15.4 ± 11 ns
(results under the cutoff value of 10) (2) (1)
*Mann-Whitney U.
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lated using the formula [(d1/u1) / (d1/u1 + d2/u2)], where
d = digested, u = undigested sample, and the two allele
peaks (1 and 2) are compared [25]. Inactivation ratios less
than 70:30 were considered random. Ratios greater than
or equal to 70:30 and less than or equal to 90:10 were con-
sidered moderately skewed. Ratios greater than 90:10 were
considered highly skewed [26].Table 3 Somatosensory evoked responses according to the p
heterozygote women
Somatosensory evoked responses
Upper Limbs (N20, or somatosensory cortex
contralateral to the wrist stimulated) in ms
Mean ± sd
Above the cutoff value of
Lower Limbs (P40, or somatosensory cortex
ipsilateral to the tibial nerve stimulated) in ms
Mean ± sd
Above the cutoff value of
* Mann-Whitney U; m/s = meters per second; mV – milivolts; μV = microvolts.Statistical analyses
Patient characteristics are given as mean ± SD and range,
when applicable. Categorical variables were represented
by absolute and relative frequencies and were compared
through Fisher exact test. The majority of continuous
variables did not show a normal distribution on the
Shapiro-Wilk test, and therefore were tested by Mann-









19.2 ± 1.1 20.1 ± 4.2 18 ± 0.9 ns *
20.5 ms 6/25 6/23 0/2 ns #
38 ± 2,5 55.3 ± 32.8 38.9 ± 3.8 ns *
41,5 ms 18/25 17/23 1/2 ns #
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Forty five heterozygote women (belonging to 25 families)
had been detected by molecular studies in our institu-
tion, from 2008 to 2013. Thirty three heterozygotes (or
73% of the total heterozygotes detected in our region)
gave their consent and were included in this study. The
another 27% (12 women) were lost: six were not found
by two phone calls and letter, two refused to participate
in the study and another four fulfilled exclusion criteria.
The mean ± sd ages of the 33 participants and of the 12
non-participants, in 2013, were of 41.2 ± 11.9 and 40.9 ±
15, respectively (ns, t test). Twenty-nine of the 33 partic-
ipants classified themselves as symptomatic and four, as
asymptomatic, after learning about X-ALD symptoms
in females. Their general characteristics are present in
Table 1.
Symptomatic were significantly older and presented
worse JOA and SSPROM scores and higher disabilityA C
B D
Figure 1 Associations relating JOA and SSPROM scales to independen
responses. (A and B) Disease duration of symptomatic heterozygotes. (C
evoked responses of lower limbs of all heterozygotes.scores than asymptomatic women. Significant differ-
ences in SSPROM scores were due to a high proportion
of symptomatic females (27/29) with spasticity/hyperre-
flexia; and to motor disabilities (Table 1). The auto-
classification and the disability scores did not perfectly
match: normal scores in the overall disability evaluation
were obtained in all four asymptomatic but also in 15/29
symptomatic women. Overall disability was related to
SSPROM and JOA scores, but not to age, age at onset
of symptoms, neurophysiologic studies and other bio-
markers (data not shown).
Among symptomatic women, although SSPROM corre-
lated with age and DD, only DD was maintained on linear
regression (r = −0.73, p = 0.0001, Spearman; B = −1.91,
EP = 0.28). When all heterozygote women were ana-
lyzed together, the association with age was confirmed
(r = −0.65, p = 0.0001, Spearman; B = −0.43, EP = 0,10,
by Linear regression) (Figures 1A and 1C).
Similar associations were found regarding to JOA.
Among symptomatic women, although JOA scores were
at first correlated with age, AO and DD, only DD was
significantly related to JOA on stepwise linear regression
(r = − 0.61, p < 0.001, Spearman; B = −0.37; EP = 0.07).E
t variables age, disease duration and somato-sensory evoked
and D) Age at examination all heterozygotes. (E) Somato-sensory
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correlated with age (r = −0.68, p = 0.0001, Spearman;
B = −0.09; EP = 0.02, Linear regression) (Figures 1B and 1D).
Mean ± sd of disease severity, or 1/(SSPROM x DD),
among symptomatic women, were 3.7 ± 2.6. This score
did not correlate with age or any other parameters.
Symptomatic classification produced more associa-
tions with independent parameters than the disability
classification, in this cohort. Due to that, it was main-
tained as the stratification criteria between the present
heterozygote women, when necessary.
Nerve conduction studies
Twenty-two out of 33 heterozygotes (20 symptomatic
and 2 asymptomatic women) performed neurophysio-
logic studies. The others denied for personal reasons.
Nineteen (including one asymptomatic heterozygote) pre-
sented at least one altered proof. Results are presented in
Table 2.
All m-NCV and most of s-NCV were normal, and
there were no correlations between NCVs and symptom-
atic status, age, AO, DD, disability status, JOA, SSPROM,
disease severity, inactivation studies or plasma NSE con-
centrations (data not shown). Twelve out of 20 symptom-
atic heterozygotes showed reduced s-NCV of the median
nerve, measured on the elbow. This finding was unrelated
to any variable under study (data not shown).
No evidence of generalized axonal damage was found in
any of the women studied, since the majority of CMAPs
and SNAPs amplitudes were between the normal range.
The amplitude of fibular superficial nerve SNAPs corre-
lated with AO among the heterozygotes (r = 0.55, p =
0.015, Spearman).
Somatosensory evoked responses
Twenty-five heterozygote females (including those 22 fe-
males with nerve studies) were tested for SSE. Eighteen
(17 symptomatic) presented delayed latencies in the cen-
tral ascending conduction studies starting on the lower
limbs (evoked potential P40) (Table 3). Latencies of the
evoked potentials were not related to age, disability, dis-
ease severity or to the symptomatic status of the hetero-
zygote women (ns, Spearman and Mann-Whitney U
tests). SSPROM correlated weakly with lower limbs
evoked potential latencies (r = −0.47, p = 0.018, Spear-
man, Figure 1E).
Mutations found in ABCD1 gene
The mutations detected on ABCD1 gene are depicted on
Additional file 1: Table S1. These mutations were strati-
fied according to their exonic position in the gene as
well as divided according to their severity in missense or
nonsense/frameshift. Mutation severity or position did
not correlate either to age at onset of symptoms or todisease severity (Mann-Whitney U and Kruskal-Wallis,
data not shown).
X Chromosome inactivation patterns
Twenty heterozygotes were informative in the technique ap-
plied to determine the inactivation pattern. Six had a skewed
inactivation pattern of 70:30 or more. Skewed inactivation
was not associated to symptomatic state (ns, Fisher exact
test), disability, SSPROM, JOA, disease severity (ns, Spear-
man) or AO (ns, Linear Regression). A curious trend to re-
late larger skewing with age was also seen (r = 0.37, p = 0.1,
Spearman).
NSE
The medium ± sd values of NSE were higher in hetero-
zygotes than in controls (12.9 ± 7 versus 7.2 ± 7 ng/ml,
p = 0.012, Mann-Whitney U, Figure 2). Both heterozy-
gote and control groups had similar ages (41.2 ± 11.9
and 35.5 ± 10.4 years, ns, M-W U).
NSE was not correlated with age, either among all
women or just among heterozygotes. No correlations
were found between NSE and AO, disability or symp-
tomatic status, inactivation studies, position of mutation
in ABCD1 gene, SSPROM, JOA, disease severity, evoked
responses or other neurophysiology parameters (data
not shown).
VLCFA
VLCFA had been determined at the time of diagnosis of
the present 33 heterozygotes, sometimes several years
before the present evaluation. Their mean ± sd ages at
the collection were of 30 ± 11.3 (range: 7 to 43) years-
old. In the case of symptomatic women, for whom the
symptom onset has been determined as year zero, blood
collections were done at a −3.8 ± 4.5 (range: -12 to 3)
years from the start of their symptoms. Correlations of
VLCFA levels with age at the time of blood collection
and with time from disease start were then tested. There
were direct correlations between age and both C26:0
and VLCFA discriminant factor (r = 0.58, p = 0.011 and
r = 0.60, p = 0.007, Spearman, Additional file 2: Figure S1).
Discussion
We examined 73% of all known heterozygote women for
X-ALD followed in our institution, and detected signifi-
cant clinical and neurophysiologic impairments in 87%
of them. The clinical scales JOA and SSPROM were able
to differentiate symptomatic from asymptomatic hetero-
zygotes. Both scales were associated with DD of the
symptomatic cases and with age in the overall group.
Abnormalities in somatosensory evoked responses, mostly
from the lower limbs, were quite frequent. A plasma pro-
tein related to neuronal damage, NSE, was associated with
the heterozygote state. All these might be candidates as
Figure 2 NSE among the X-ALD heterozygotes and the control women.
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for X-ALD.
Quantifying physical disability and neurologic burden
is essential to understanding the progression rate of any
disease [5]. In the present report, three levels of conse-
quences related to the heterozygote state for X-ALD
were measured: subjective perception, neurologic im-
pairment and disability. Being symptomatic is a yes/or/
no subjective perception. Neurologic impairment was
measured by JOA and SSPROM scales, and by neuro-
physiologic studies. Disability reflects dysfunctions on
performance and activity; we measured it by using spe-
cific domains of SSPROM. Disability needs an arbitrary
cutoff. Disability scores obtained in the present group
were very mild. Due to that, we decided to include even
small disabilities in the dichotomic, positive group. We
have then stratified heterozygote women both by their
symptomatic and disability states.
We have obtained 29 symptomatic and 4 asymptom-
atic women; in contrast, there were 14 disabled and 19
non-disabled women. Although the disability stratifica-
tion seemed to produce more even groups, it failed to be
associated with age or with DD. In contrast, symptom-
atic status correlated with age, JOA, and SSPROM;
moreover, DD - in other words, the duration of symp-
toms - correlated with both JOA and SSPROM. There-
fore, symptomatic classification produced more useful
information than its counterpart (disability).
Neurological impairment was better evaluated by clin-
ical scales than by neurophysiology. Both JOA and
SSPROM scales were able to discriminate symptomatic
from asymptomatic heterozygotes, with almost no overlap,correlated very well with DD in the symptomatic group,
and with age in the overall group.
The lack of any substantial alterations on peripheral
neurophysiology reported here corroborates the findings
of Schmidt and Cols [8]. One interesting finding was the
direct correlation of fibular SNAP with AO. Reduced
SNAP is commonly related to an inherent susceptibility
of the fibular nerve for entrapments. Why did it correl-
ate with AO, is an issue that deserves investigation in
other heterozygotes.
After clinical scores, the SSER of lower limbs have
shown the most prevalent abnormalities in heterozygote
women. Similar results have been seen by others [8,27-30]
SSER of lower limbs correlated with SSPROM and this
might be taken as an external validation for SSPROM
usefulness among X-ALD heterozygotes. On the other
hand, SSER were not associated with any other meas-
urement of disease progression like age and disease
duration.
X chromosome inactivation has been studied as a modi-
fying factor that could influence clinical presentation in
women with X linked disorders. Relating a skewed inacti-
vation in peripheral leukocytes to a neuronal disorder, as
in the heterozygote women with X-ALD, is a complex hy-
pothesis. If this association would exist, at least two pos-
sible mechanisms should be invoked: a good mirroring
between neurons and leukocytes, where a skewed X in-
activation in neurons would be related to differences in
clinical presentation; and/or an intercellular mechanism,
operating from skewed cells other than neurons. Differ-
ently from some authors [12] but similar to others [11],
we did not find any association between inactivation and
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trend relating an increased skewing with age, which is in
accordance with literature [31].
VLCFA also increased with age, at least in this cohort,
whose blood collections had been done between 7 and
43 years of age. Other authors have observed a similar
finding in this age group, with decreasing VLCFA con-
centrations in women older than 50 years old [32]. Al-
though both VLFCA and skewing inactivation increased
with age in our group, no association was found with in-
creasing neurological symptoms.
NSE is a cytoplasmatic glycolytic enzyme found in
neurons and cells with neuroendocrine differentiation.
Since NSE is not physiologically secreted, an increase of
its serum concentrations can be associated with struc-
tural damage to neuronal cells [33]. NSE concentrations
were higher in heterozygote women than in controls, in
the present study. Since NSE was not associated with
symptomatic or disability status, nor with any variable
related to disease progression, we were not able to show
a clear potential for NSE as a biomarker for disease pro-
gression in this disease.
According to former studies, around 50% of X-ALD
heterozygotes showed some degree of neurologic in-
volvement [6]. Our results were quite different: 87%
were symptomatic, with neurological impairments as
measured by JOA and SSPROM scores. Our large pro-
portion of symptomatic women was quite surprising. Al-
though one cannot rule out a selection bias favoring the
recruitment of symptomatic heterozygotes, the simili-
tude between the mean ages of the recruited and of the
non-recruited heterozygote women works against this
conjecture. Our rates might be explained by different
measurements of neurological burden: perhaps former
reports relied on disabilities rather than impairments.
Our experience showed that disabilities were mild in
general, with the exception of sphincter dysfunctions
(Table 1). Impairments, on the other hand, were clearly
present, the major impact being the corticospinal in-
volvement (Table 1).
Emotional issues should also be remembered. Male
X-ALD is a catastrophic disease for families. A mother
or a female caregiver of an affected boy usually lives in
very stressful conditions, where priorities are put in
hemizygote men rather than in her well-being. Maybe
the actual numbers of symptomatic heterozygote fe-
males had been previously underestimated, due to a
hasty report of these women about their healthy states.
The hypothesis that the majority of heterozygote fe-
males will present a neurologic impairment is not neg-
ligible. Moreover, the associations between JOA and
SSPROM with age might suggest that the symptomatic
status is a matter of time and that, as heterozygote fe-
males grow older, they get symptomatic.With the prominent involvement of pyramidal tracts,
X-ALD presenting in symptomatic heterozygotes and as
male AMN, can be seen as one form of complicated
spastic paraplegia (SPG) [34]. Therapeutic trials in men
and women with AMN and in SPGs in general are ex-
pected in a near future, and it will be important to de-
cide what scales to use on them. Recently, some studies
have measured the neurological impairment of SPGs by
the Spastic Paraplegia Rating Scale (SPRS) [35]. In con-
trast, we have used two instruments fitted to measure
both disability and impairment, scales that might be
called disease severity scoring systems (or 3S): the scales
JOA and SSPROM. SSPROM was developed to follow
metabolic progressive myelopathies such as AMN; so
far, only the present and the description studies have
used it [16]. JOA was developed to follow cervical com-
pression myelopathies [15], and it is probably the most
used neurologic scale for myelopathies so far. For a clin-
ical trial, several properties of the chosen scale will be
essential to guarantee the best design, such as validity,
reliability and sensitivity to change. At this very moment,
it is not clear what scale will be best fitted to a future
trial for AMN. Comparisons of these characteristics
among different scales are needed and should be done in
a near future.
Conclusions
Neurologic impairments are frequent and are clearly re-
lated to age and to the CNS involvement, in heterozy-
gote females. SSER of lower limbs and plasma NSE
concentrations were altered in the majority of heterozy-
gote females. Since they did not differentiate between
symptomatic and asymptomatic heterozygotes, nor were
related to age or disease duration, we cannot postulate
them as good candidates as biomarkers of disease progres-
sion. VLFCA and skewing inactivation were also unable to
separate symptomatic from asymptomatic heterozygotes.
Both increased with age, but dissociated from the increas-
ing neurological symptoms. Among the number of poten-
tial biomarkers of disease progression, JOA and SSPROM
presented the most robust associations with disease dur-
ation and age. Besides that, SSPROM correlated with
SSER of lower limbs. We suggest that JOA and SSPROM
might be valuable instruments in future natural history
studies in heterozygotes for X-ALD.Additional files
Additional file 1: Table S1. Mutations found at ABCD1 gene in the
present X-ALD heterozygote women, and the distribution of ages at
examination and at onset of symptoms.
Additional file 2: Figure S1. Associations between age and (6A) C26:00
plasma levels and (6B) VLCFA discriminant factor 3,805(C24:0/C22:0) +
5,296(C26:0/C22:0) + 5,15(C26:0).
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